A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology

Cancer Prevention Research

Volumn 7, Issue 5, 2014, Pages 496-504

  Linden, Kenneth G ^a,b   Leachman, Sancy A ^d   Zager, Jonathan S ^e   Jakowatz, James G ^a   Viner, Jaye L ^f,j   McLaren, Christine E ^a,b   Barr, Ronald J ^b   Carpenter, Philip M ^a   Chen, Wen Pin ^a   Elmets, Craig A ^g   Tangrea, Joseph A ^h   Lim, Sung Jig ⁱ   Cochran, Alistair J ^c   Meyskens Jr , Frank L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f Huntsman Cancer Institute University of Utah ^*  (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ Kyung Hee University   (South Korea)

^j CURIS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; CHOLESTEROL; CREATINE KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NERVE CELL ADHESION MOLECULE; PLACEBO; TRANSCRIPTION FACTOR RELA; TRIACYLGLYCEROL; UVOMORULIN; VASCULOTROPIN; HYPOCHOLESTEROLEMIC AGENT; TUMOR MARKER;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DYSPLASTIC NEVUS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRECANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; BLOOD; CELL TRANSFORMATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; MIDDLE AGED; NEVUS; PATHOLOGY; SKIN NEOPLASMS;

ADULT; ANTICHOLESTEREMIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOVASTATIN; MALE; MELANOMA; MIDDLE AGED; NEVUS; PLACEBOS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84900807809     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0189     Document Type: Article

References (30)

1. Demierre MF, Nathanson L. Chemoprevention of melanoma: an unexplored strategy. J Clin Oncol 2003;21:158-65.
2. Splichal JE, Stamm JA, Ornstein DL. The statins: multifunctional antithrombotic and antineoplastic drugs. Semin Thromb Hemost 2003;29:259-74. (Pubitemid 36776188)
3. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8. (Pubitemid 29362514)
4. Jagtap D, Rosenberg CA, Martin LW, Pettinger M, Khandekar J, Lane D, et al. Prospective analysis of association between use of statins and melanoma risk in the Women's Health Initiative. Cancer 2012;118:5124-31.
5. Bonovas S, Nikolopoulos G, Filioussi K, Peponi E, Bagos P, Sitaras NM. Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials. Eur J Epidemiol 2010;25:29-35.
6. Freeman SR, Drake AL, Heilig LF, Graber M, McNealy K, Schilling LM, et al. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. J Natl Cancer Inst 2006;98:1538-46. (Pubitemid 44680905)
7. Koomen ER, Joosse A, Herings RM, Casparie MK, Bergman W, Nijsten T, et al. Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin? Eur J Cancer 2007;43:2580-9. (Pubitemid 350086942)
8. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367:1792-802.
9. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003;9:10-9. (Pubitemid 36109711)
10. Kidera Y, Tsubaki M, Yamazoe Y, Shoji K, Nakamura H, Ogaki M, et al. Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway. J Exp Clin Cancer Res 2010;29:127.
11. Pich C, Teiti I, Rochaix P, Mariamé B, Couderc B, Favre G, et al. Statins reduce melanoma development and metastasis through MICA overexpression. Front Immunol 2013;4:62.
12. Slominski A, Gomez-Sanchez CE, Foecking MF, Wortsman J. Metabolism of progesterone to DOC, corticosterone and 18OHDOC in cultured human melanoma cells. FEBS Lett 1999;455:364-6. (Pubitemid 29333068)
13. Slominski A, Zjawiony J, Wortsman J, Semak I, Stewart J, Pisarchik A, et al. A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin. Eur J Biochem 2004;271:4178-88. (Pubitemid 39506746)
14. Rhodes AR, Harrist TJ, Day CL, Mihm MC Jr, Fitzpatrick TB, Sober AJ. Dysplastic melanocytic nevi in histologic association with 234 primary cutaneous melanomas. J Am Acad Dermatol 1983;9:563-74. (Pubitemid 13007755)
15. Greene MH, Clark WH Jr, Tucker MA, Kraemer KH, Elder DE, Fraser MC. High risk of malignant melanomain melanoma-prone families with dysplastic nevi. Ann Intern Med 1985;102:458-65. (Pubitemid 15109001)
16. Consensus conference: Precursors to malignant melanoma. JAMA 1984;251:1864-6.
17. Pocock SJ. Clinical trials: a practical approach. John Wiley & Sons: New York; 1983.
18. Barr RJ, Linden KG, Rubinstein G, Cantos KA. Analysis of heterogeneity of atypia within melanocytic nevi. Arch Dermatol 2003;139:289-92. (Pubitemid 36330575)
19. Buckmeier JA, Einspahr JG, Hart NK, Bozzo PA, Bangert JL, Fruehauf JP, et al. Differential expression of VEGF, CD31, CD105, and p53 in benign nevi, dysplastic nevi, and primary melanoma. Phoenix, AZ: AACR Frontiers in Cancer Prevention Research; 2003. #1635; p. 30.
20. Skaletz-Rorowski A, Walsh K. Statin therapy and angiogenesis. Curr Opin Lipidol 2003;14:599-603. (Pubitemid 41623189)
21. Moretti S, Massobrio R, Brogelli L, Novelli M, Giannotti B, Bernengo MG. Ki67 antigen expression correlates with tumor progression and HLA-DR antigen expression in melanocytic lesions. J Invest Dermatol 1990;95:320-4. (Pubitemid 20261866)
22. Rieger E, Hofmann-Wellenhof R, Soyer HP, Kofler R, Cerroni L, Smolle J, et al. Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. A quantitative immunohistochemical study. J Cutan Pathol 1993;20:229-36. (Pubitemid 23210541)
23. Smolle J, Soyer HP, Kerl H. Proliferative activity of cutaneous melanocytic tumors defined by Ki-67 monoclonal antibody. A quantitative immunohistochemical study. Am J Dermatopathol 1989;11:301-7. (Pubitemid 19185400)
24. Kaleem Z, Lind AC, Humphrey PA, Sueper RH, Swanson PE, Ritter JH, et al. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas? Mod Pathol 2000;13:217-22. (Pubitemid 30207505)
25. Rudolph P, Schubert C, Schubert B, Parwaresch R. Proliferation marker Ki-S5 as a diagnostic tool in melanocytic lesions. J Am Acad Dermatol 1997;37:169-78. (Pubitemid 27355700)
26. Lee SJ, Ha MJ, Lee J, Nguyen P, Choi YH, Pirnia F, et al. Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells. J Biol Chem 1998;273:10618-23.
27. McNulty SE, del Rosario R, Cen D, Meyskens FL Jr, Yang S. Comparative expression of NFkappaB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell Res 2004;17:173-80. (Pubitemid 38419645)
28. Elmore E, Jain A, Siddiqui S, Tohidian N, Meyskens FL, Steele VE, et al. Development and characteristics of a human cell assay for screening agents for melanoma prevention. Melanoma Res 2007;17:42-50. (Pubitemid 46145479)
29. Noether GE. Sample size determination for some common nonparametric statistics. JASA 1987;82:645-7.
30. Holm S. A simple sequentially rejective multiple tests procedure. Scand J Statist 1979;6:65-70.